Per Lundkvist

Successful Management of Two Consecutive Pregnancies With Maternal-Fetal Phenylketonuria: Lessons From Clinical Practice

Lundkvist, Per; Malmberg, Karin Blom; Lindström, Linda; Kindmark, Andreas

Ingår i JIMD Reports, 2026

• DOI för Successful Management of Two Consecutive Pregnancies With Maternal-Fetal Phenylketonuria: Lessons From Clinical Practice
• Ladda ner fulltext (pdf) av Successful Management of Two Consecutive Pregnancies With Maternal-Fetal Phenylketonuria: Lessons From Clinical Practice

Proximity extension assay inflammatory profiling cannot distinguish the presence of residual C-peptide in patients with long-standing type 1 diabetes

Anvari, Ebrahim; Lundkvist, Per; Singh, Kailash; Espes, Daniel

Ingår i Acta Diabetologica, s. 1987-1996, 2025

• DOI för Proximity extension assay inflammatory profiling cannot distinguish the presence of residual C-peptide in patients with long-standing type 1 diabetes
• Ladda ner fulltext (pdf) av Proximity extension assay inflammatory profiling cannot distinguish the presence of residual C-peptide in patients with long-standing type 1 diabetes

Long-term treatment with gamma-aminobutyric acid (GABA) fails to regain beta-cell function in longstanding type 1 diabetes: results from a randomized trial

Hill, Henrik; Lundkvist, Per; Tsatsaris, Georgios; Birnir, Bryndis et al.

Ingår i Scientific Reports, 2025

• DOI för Long-term treatment with gamma-aminobutyric acid (GABA) fails to regain beta-cell function in longstanding type 1 diabetes: results from a randomized trial
• Ladda ner fulltext (pdf) av Long-term treatment with gamma-aminobutyric acid (GABA) fails to regain beta-cell function in longstanding type 1 diabetes: results from a randomized trial

Predictive biomarkers of rapidly developing insulin deficiency in children with type 1 diabetes

Lundkvist, Per; Grönberg, Annika; Carlsson, Per-Ola; Ludvigsson, Johnny et al.

Ingår i BMJ Open Diabetes Research & Care, 2024

• DOI för Predictive biomarkers of rapidly developing insulin deficiency in children with type 1 diabetes
• Ladda ner fulltext (pdf) av Predictive biomarkers of rapidly developing insulin deficiency in children with type 1 diabetes

Endogenous Levels of Gamma Amino-Butyric Acid Are Correlated to Glutamic-Acid Decarboxylase Antibody Levels in Type 1 Diabetes

Hill, Henrik; Elksnis, Andris; Lundkvist, Per; Ubhayasekera, Kumari et al.

Ingår i Biomedicines, 2022

• DOI för Endogenous Levels of Gamma Amino-Butyric Acid Are Correlated to Glutamic-Acid Decarboxylase Antibody Levels in Type 1 Diabetes
• Ladda ner fulltext (pdf) av Endogenous Levels of Gamma Amino-Butyric Acid Are Correlated to Glutamic-Acid Decarboxylase Antibody Levels in Type 1 Diabetes

Successful Management of Two Consecutive Pregnancies With Maternal-Fetal Phenylketonuria: Lessons From Clinical Practice

Lundkvist, Per; Malmberg, Karin Blom; Lindström, Linda; Kindmark, Andreas

Ingår i JIMD Reports, 2026

• DOI för Successful Management of Two Consecutive Pregnancies With Maternal-Fetal Phenylketonuria: Lessons From Clinical Practice
• Ladda ner fulltext (pdf) av Successful Management of Two Consecutive Pregnancies With Maternal-Fetal Phenylketonuria: Lessons From Clinical Practice

Proximity extension assay inflammatory profiling cannot distinguish the presence of residual C-peptide in patients with long-standing type 1 diabetes

Anvari, Ebrahim; Lundkvist, Per; Singh, Kailash; Espes, Daniel

Ingår i Acta Diabetologica, s. 1987-1996, 2025

• DOI för Proximity extension assay inflammatory profiling cannot distinguish the presence of residual C-peptide in patients with long-standing type 1 diabetes
• Ladda ner fulltext (pdf) av Proximity extension assay inflammatory profiling cannot distinguish the presence of residual C-peptide in patients with long-standing type 1 diabetes

Long-term treatment with gamma-aminobutyric acid (GABA) fails to regain beta-cell function in longstanding type 1 diabetes: results from a randomized trial

Hill, Henrik; Lundkvist, Per; Tsatsaris, Georgios; Birnir, Bryndis et al.

Ingår i Scientific Reports, 2025

• DOI för Long-term treatment with gamma-aminobutyric acid (GABA) fails to regain beta-cell function in longstanding type 1 diabetes: results from a randomized trial
• Ladda ner fulltext (pdf) av Long-term treatment with gamma-aminobutyric acid (GABA) fails to regain beta-cell function in longstanding type 1 diabetes: results from a randomized trial

Predictive biomarkers of rapidly developing insulin deficiency in children with type 1 diabetes

Lundkvist, Per; Grönberg, Annika; Carlsson, Per-Ola; Ludvigsson, Johnny et al.

Ingår i BMJ Open Diabetes Research & Care, 2024

• DOI för Predictive biomarkers of rapidly developing insulin deficiency in children with type 1 diabetes
• Ladda ner fulltext (pdf) av Predictive biomarkers of rapidly developing insulin deficiency in children with type 1 diabetes

Endogenous Levels of Gamma Amino-Butyric Acid Are Correlated to Glutamic-Acid Decarboxylase Antibody Levels in Type 1 Diabetes

Hill, Henrik; Elksnis, Andris; Lundkvist, Per; Ubhayasekera, Kumari et al.

Ingår i Biomedicines, 2022

• DOI för Endogenous Levels of Gamma Amino-Butyric Acid Are Correlated to Glutamic-Acid Decarboxylase Antibody Levels in Type 1 Diabetes
• Ladda ner fulltext (pdf) av Endogenous Levels of Gamma Amino-Butyric Acid Are Correlated to Glutamic-Acid Decarboxylase Antibody Levels in Type 1 Diabetes

Early Changes in Adipose Tissue Morphology, Gene Expression, and Metabolism After RYGB in Patients With Obesity and T2D

Katsogiannos, Petros; Kamble, Prasad G.; Boersma, Greta J.; Karlsson, F. Anders et al.

Ingår i Journal of Clinical Endocrinology and Metabolism, s. 2601-2613, 2019

• DOI för Early Changes in Adipose Tissue Morphology, Gene Expression, and Metabolism After RYGB in Patients With Obesity and T2D

Glucagon Levels During Short-Term SGLT2 Inhibition Are Largely Regulated by Glucose Changes in Patients With Type 2 Diabetes.

Lundkvist, Per; Pereira, Maria J.; Kamble, Prasad G.; Katsogiannos, Petros et al.

Ingår i Journal of Clinical Endocrinology and Metabolism, s. 193-201, 2019

• DOI för Glucagon Levels During Short-Term SGLT2 Inhibition Are Largely Regulated by Glucose Changes in Patients With Type 2 Diabetes.

FKBP5 expression in human adipose tissue: potential role in glucose and lipid metabolism, adipogenesis and type 2 diabetes

Sidibeh, Cherno O; Pereira, Maria J; Abalo, Xesus; Boersma, Gretha J. et al.

Ingår i Endocrine, s. 116-128, 2018

• DOI för FKBP5 expression in human adipose tissue: potential role in glucose and lipid metabolism, adipogenesis and type 2 diabetes
• Ladda ner fulltext (pdf) av FKBP5 expression in human adipose tissue: potential role in glucose and lipid metabolism, adipogenesis and type 2 diabetes

Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study

Eriksson, Jan W.; Lundkvist, Per; Jansson, Per-Anders; Johansson, Lars et al.

Ingår i Diabetologia, s. 1923-1934, 2018

• DOI för Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study
• Ladda ner fulltext (pdf) av Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study

Role of peroxisome proliferator-activated receptor gamma Pro12Ala polymorphism in human adipose tissue: assessment of adipogenesis and adipocyte glucose and lipid turnover.

Kamble, Prasad G.; Pereira, Maria J; Gustafsson, Stefan; Lundkvist, Per et al.

Ingår i Adipocyte, s. 285-296, 2018

• DOI för Role of peroxisome proliferator-activated receptor gamma Pro12Ala polymorphism in human adipose tissue: assessment of adipogenesis and adipocyte glucose and lipid turnover.
• Ladda ner fulltext (pdf) av Role of peroxisome proliferator-activated receptor gamma Pro12Ala polymorphism in human adipose tissue: assessment of adipogenesis and adipocyte glucose and lipid turnover.

Direct effects of glucagon on human adipose tissue metabolism

Pereira, Maria J; Boersma, Greta J.; Kamble, Prasad G.; Lundkvist, Per et al.

Ingår i Diabetologia, 2018

A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss

Pereira, Maria J; Lundkvist, Per; Kamble, Prasad G.; Lau, Joey et al.

Ingår i Diabetes Therapy, s. 1511-1532, 2018

• DOI för A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss
• Ladda ner fulltext (pdf) av A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss

Genotype-based recall to study metabolic effects of genetic variation: a pilot study of PPARG Pro12Ala carriers

Kamble, Prasad G.; Gustafsson, Stefan; Pereira, Maria J; Lundkvist, Per et al.

Ingår i Upsala Journal of Medical Sciences, s. 234-242, 2017

• DOI för Genotype-based recall to study metabolic effects of genetic variation: a pilot study of PPARG Pro12Ala carriers
• Ladda ner fulltext (pdf) av Genotype-based recall to study metabolic effects of genetic variation: a pilot study of PPARG Pro12Ala carriers

Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes

Lundkvist, Per; Sjöström, C. David; Amini, Sam; Pereira, Maria J. et al.

Ingår i Diabetes, obesity and metabolism, s. 49-60, 2017

• DOI för Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes
• Ladda ner fulltext (pdf) av Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes

Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year

Lundkvist, Per; Pereira, Maria J; Katsogiannos, Petros; Sjöström, C. David et al.

Ingår i Diabetes, obesity and metabolism, s. 1276-1288, 2017

• DOI för Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year
• Ladda ner fulltext (pdf) av Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year

PPARG Pro12Ala variant in relation to adipose tissue metabolism and differentiation: a small genotype-based recall study

Kamble, Prasad G.; Pereira, Maria J; Gustafsson, Stefan; Lundkvist, Per et al.

Ingår i Diabetologia, 2017

Glucose homeostasis and whole-body insulin resistance improved 4 weeks after gastric bypass surgery in type 2 diabetes, whereas adipose tissue metabolism was unchanged

Katsogiannos, Petros; Boersma, Greta J.; Pereira, Maria J; Lundkvist, Per et al.

Ingår i Diabetologia, 2017

Glucagon levels during short-term SGLT2 inhibition are largely regulated by plasma glucose changes

Lundkvist, Per; Pereira, Maria J; Kamble, Prasad G.; Katsogiannos, Petros et al.

Ingår i Diabetologia, 2017

Effects of dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, and free omega-3 carboxylic acids on liver steatosis and hepatocyte damage biomarkers in Type 2 diabetes patients with non-alcoholic fatty liver disease

Oscarsson, Jan; Lundkvist, Per; Jansson, Per-Anders E.; Johansson, Lars et al.

Ingår i Hepatology, 2016

One year of treatment with dapagliflozin QD plus exenatide QW in obese adults without diabetes: results of an open-label extension study

Eriksson, Jan W.; Lundkvist, Per; Sjöström, C.; Katsogiannos, Petros et al.

Ingår i Diabetologia, 2016

Metabolic effects of dapagliflozin QD and exenatide QW in obese adults without diabetes: a 24-week randomised placebo-controlled phase 2 study

Lundkvist, Per; Amini, Sam; Lau Börjesson, Joey; Pereira, Maria J. et al.

Ingår i Diabetologia, 2016

Metabolic and endocrine effects of SGLT2 inhibition

Lundkvist, Per

2019

• Ladda ner fulltext (pdf) av Metabolic and endocrine effects of SGLT2 inhibition